Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis (DISTOL-PK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00848939|
Recruitment Status : Completed
First Posted : February 20, 2009
Last Update Posted : October 23, 2012
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Systemic Sclerosis||Drug: treprostinil diethanolamine||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||April 2010|
|Experimental: treprostinil diethanolamine||
Drug: treprostinil diethanolamine
Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
Drug: treprostinil diethanolamine
Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
- Cohort 1: treprostinil pharmacokinetics in patients with systemic sclerosis following single oral administration of a 1 mg treprostinil diethanolamine SR dose. [ Time Frame: pre-24hrs post dose ]
- Cohort 2: treprostinil pharmacokinetics at dose levels of 2 mg BID and 4 mg BID, respectively, in patients with systemic sclerosis following repeated oral administration of treprostinil diethanolamine SR tablets [ Time Frame: 0-12 hrs post-dose ]
- adverse event monitoring [ Time Frame: Cohort 1:Day 0 to Day 2; Cohort 2: Day 0 to Day 47 ]
- clinical laboratories [ Time Frame: Cohort 1: Day 0 and Day 2; Cohort 2: Day 0 and Day 47 ]
- Cohort 2: Raynauds Phenomenon Visual Analoge Scale [ Time Frame: 7 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject gives voluntary written informed consent to participate in the study.
- Subject has been diagnosed with systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria.
- Males and females age greater than 18 years at time of Screening.
- Presence of active digital ulcer OR history of digital ulcer occurring within past 6 months at time of Screening and poorly controlled Raynaud's phenomenon (as documented by patient report of 6-10 episodes per week).
- Females of childbearing potential must be willing to use two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at Screening, confirmed at Baseline if separate visits. Women who are surgically sterile or have been post-menopausal for at least 2 years are not considered to be of child-bearing potential.
- Subject agrees to abstain from consuming grapefruit containing food or beverages for 3 days prior to Baseline and until discharge from the study.
- Subject is able to communicate effectively with study personnel and be considered reliable, willing and cooperative in terms of compliance with the protocol requirements.
- Has diagnosis of pulmonary arterial hypertension and receiving approved or investigational therapies for PAH, including endothelin receptor antagonists, phosphodiesterase inhibitors, or prostacyclin analogues.
- Body weight less than 40 kg at time of Screening, confirmed at Baseline.
- The subject has a history of postural hypotension, unexplained syncope, a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
- Hemoglobin concentration less than 75% of the lower limit of the normal range at time of Screening.
- AST and/or ALT concentrations greater than 3 times upper limit of normal (ULN) at time of Screening.
- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.
- Intractable diarrhea, severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening, or any severe organ failure (e.g., lung, kidney) or any life-threatening condition.
- Pregnancy or breast-feeding.
- Overlap with another connective tissue disease that could affect rest pain and hand function (e.g. diabetes mellitus, rheumatoid arthritis).
- Sympathectomy of the upper limb performed within 12 months of Baseline.
- Receipt of parenteral prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months for conditions including PAH, rest pain and / or digital ulcers.
- Treatment with gemfibrozil, glitazones, or cyclophosphamide within 1 week prior to Baseline.
- Treatment with rifampin within 4 weeks prior to Baseline.
- Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline.
- Received systemic antibiotics to treat infection of digital ulcers within 2 weeks prior to Baseline.
- Treatment with phosphodiesterase inhibitors such as sildenafil, except for intermittent treatment of male erectile dysfunction.
- Received an investigational product within 1 month preceding Screening.
- Known hypersensitivity to oral treprostinil or any of the excipients.
- Cigarette smoking at any level within the past 6 months prior to Screening.
- Any condition that could prevent compliance with the protocol or adherence to therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00848939
|United States, Maryland|
|Johns Hopkins Scleroderma Center|
|Baltimore, Maryland, United States, 21224|
|United States, Massachusetts|
|Boston University School of Medicine Rheumatology Arthritis Center|
|Boston, Massachusetts, United States, 02118|
|United States, Michigan|
|University of Michigan Scleroderma Program|
|Ann Arbor, Michigan, United States, 48016|
|Study Director:||Kristan Rollins, PharmD||United Therapeutics|
|Responsible Party:||United Therapeutics|
|Other Study ID Numbers:||
|First Posted:||February 20, 2009 Key Record Dates|
|Last Update Posted:||October 23, 2012|
|Last Verified:||October 2012|
Connective Tissue Diseases